Abstract 1206
Background
The Oncotype DX breast cancer assay is increasingly being used to guide treatment decisions for patients with early stage, hormone-positive, Her-2 negative breast cancer, regardless of the histologic subtype. The utility of the Oncotype DX in decision making for treatment of invasive lobular carcinoma (ILC) has not been investigated.
Methods
We performed a retrospective analysis of early stage breast cancer patients treated at Penn State Cancer Institute from 2001 to 2011 and identified 102 patients with ILC. We evaluated the clinicopathological features and compared the Recurrence Score (RS) distribution in this population to that reported by Genomic Heath for the ductal histology (Kruskal-Wallis test). Median follow-up was 4.5 years
Results
We found that the RS distribution for ILC differed significantly from that reported by Genomic Health (P
Conclusions
The Oncotype DX RS distribution in invasive lobular carcinoma is unique, differing significantly from that in invasive ductal carcinoma. Majority of patients (97.8%) have low/intermediate RS and 93.3% have RS ≤ 25 and would not be candidates for adjuvant chemotherapy. The clinical usefulness and cost-effectiveness of the Oncotype DX in guiding treatment for ILC should be further investigated.
Clinical trial identification
Legal entity responsible for the study
Jesse Felts Cristina Truica
Funding
Pink Zone and Lady Lion Basketball Breast Cancer Research Endowment and the Federal US Work Study program
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort
Presenter: Xavier Pivot
Session: Breast cancer, early
Resources:
Abstract
Presentation
Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population
Presenter: Christopher Hart
Session: Breast cancer, early
Resources:
Abstract
Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer
Presenter: Alberto Ocana Fernandez
Session: Breast cancer, early
Resources:
Abstract
Presentation
Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC)
Presenter: Luisa Carbognin
Session: Breast cancer, early
Resources:
Abstract
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study
Presenter: Antonino Musolino
Session: Breast cancer, early
Resources:
Abstract
Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)
Presenter: Steven Shak
Session: Breast cancer, early
Resources:
Abstract
Presentation
Invited discussant LBA13 and abstract 144O
Presenter: Marco Colleoni
Session: Breast cancer, early
Resources:
Presentation
Invited discussant abstracts 151PD, 152PD, 153PD, 154PD
Presenter: Karen Gelmon
Session: Breast cancer, early
Resources:
Presentation
Webcast
Invited discussant abstracts 145O and 146O
Presenter: Nadia Harbeck
Session: Breast cancer, early
Resources:
Presentation
Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC)
Presenter: Sara Hurvitz
Session: Breast cancer, early
Resources:
Abstract